VVOS - Vivos Therapeutics, Inc. Stock Price, Fair Value and News

$4.76-0.05 (-1.04%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VVOS Price Action

Last 7 days

-1.8%

Last 30 days

50.3%

Last 90 days

48.5%

Trailing 12 Months

-57.5%

VVOS RSI Chart

VVOS Valuation

Market Cap

23.3M

Price/Earnings (Trailing)

-1.85

Price/Sales (Trailing)

1.6

EV/EBITDA

-0.73

Price/Free Cashflow

-1.78

VVOS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VVOS Fundamentals

VVOS Revenue

Revenue (TTM)

14.6M

Rev. Growth (Yr)

16.93%

Rev. Growth (Qtr)

-4.79%

VVOS Earnings

Earnings (TTM)

-12.6M

Earnings Growth (Yr)

-24.99%

Earnings Growth (Qtr)

-35.54%

VVOS Profitability

EBT Margin

-86.19%

Return on Equity

-163.97%

Return on Assets

-81.89%

Free Cashflow Yield

-56.17%

VVOS Investor Care

Shares Dilution (1Y)

303.86%

Diluted EPS (TTM)

-5.68

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	13.4M	14.0M	14.6M	0
2023	16.2M	15.4M	14.5M	13.8M
2022	17.1M	16.8M	16.5M	16.0M
2021	13.3M	14.5M	15.8M	16.9M
2020	11.8M	12.2M	12.6M	13.1M
2019	0	0	0	11.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

CEO	Mr. R. Kirk Huntsman
WEBSITE	https://vivos.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	154

Vivos Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Vivos Therapeutics, Inc.? What does VVOS stand for in stocks?

VVOS is the stock ticker symbol of Vivos Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vivos Therapeutics, Inc. (VVOS)?

As of Tue Dec 24 2024, market cap of Vivos Therapeutics, Inc. is 23.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VVOS stock?

You can check VVOS's fair value in chart for subscribers.

Is Vivos Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VVOS is over valued or under valued. Whether Vivos Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Vivos Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VVOS.

What is Vivos Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 24 2024, VVOS's PE ratio (Price to Earnings) is -1.85 and Price to Sales (PS) ratio is 1.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VVOS PE ratio will change depending on the future growth rate expectations of investors.